MMWR
ACIP releases 2024 child & adolescent immunization schedule
Key updates for 2024 include:
COVID-19: Info has been revised to reflect the current COVID-19 vaccination recommendations for children and adolescents and use of the updated (2023-2024 Formula) vaccines. The number of doses needed and intervals between doses might vary on the basis of a patient’s previous vaccination history, immunocompromised status, and the vaccine product used.
Influenza: All bullets describing recommendations for persons with a history of egg allergy were removed. Persons with a history of egg allergy of any severity can be vaccinated with any influenza vaccine indicated for the recipient’s age and health status, with no additional safety considerations.
Pneumococcal: This section has been updated with new recommendations for use of 15-valent pneumococcal conjugate vaccine (PCV15), PCV20, and PPSV23. PCV13 was deleted from all sections. Chronic kidney disease, chronic liver disease, and moderate persistent or severe persistent asthma were added to the list of medical conditions that increase the risk for invasive pneumococcal disease.
Poliovirus: Language was added stating that most adolescents aged 18 years who were born and raised in the US can assume to be vaccinated against poliovirus as children. The “Special situations” section was revised to describe administering a one-time, lifetime IPV booster to adolescents aged 18 years who have completed the primary series and are at increased risk for exposure to poliovirus.
Mpox: A new section describing recommendations for use of Jynneos in adolescents aged 18 years, including sexual risk factors and vaccination during pregnancy, was added.
Meningococcal: All reference to Menactra (MenACWY-D) was removed because this vaccine is no longer distributed in the US. Information about the use of the newly licensed pentavalent meningococcal vaccine (Penbraya) was added. A link to a resource to assist HCPs with shared clinical decision-making recommendations for MenB vaccination was added.
RSV-mAb: A new section providing details on the use of nirsevimab in infants and young children was added. The “Routine immunization” section outlines the recommendations for infants aged <8 months. The “Special situations” section describes recommendations for age-eligible children who are undergoing cardiac surgery with cardiopulmonary bypass, and children ages 8 to 19 months who are at increased risk for severe RSV disease. Information describing timing of immunization, including guidance for jurisdictions with RSV seasonality that differs from most of the continental US, was included.
RSV vaccine: A new section was added outlining recommendations for maternal RSV vaccination with Abrysvo (Pfizer) using seasonal administration. HCPs should take one of two approaches to prevent severe RSV disease in infants: either administer Abrysvo (Pfizer) to pregnant persons at 32 to 36 weeks’ gestation or administer nirsevimab to the infant. Information describing vaccination timing, including guidance for jurisdictions with RSV seasonality that differs from most of the continental US, was included.
Tdap: The schedule clarifies that the Tdap dose recommended at age 11 to 12 years is the adolescent Tdap booster dose.
Source:
Wodi AP, et al. (2024, January 11). MMWR Morb Mortal Wkly Rep. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024. https://www.cdc.gov/mmwr/volumes/73/wr/mm7301a2.htm